Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC
Conditions
Interventions
KHK4083
Placebo
Locations
23
United States
Greenville, South Carolina, United States
Hradec Králové, Czechia
Znojmo, Czechia
Budapest, Hungary
Budapest, Hungary
Budapest, Hungary
Start Date
June 1, 2016
Primary Completion Date
September 1, 2018
Completion Date
October 1, 2018
Last Updated
April 26, 2024
NCT07550673
NCT05739864
NCT04338204
NCT07271069
NCT05076175
NCT06975722
Lead Sponsor
Kyowa Kirin, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions